Abbisko’s Pimicotinib Gains Priority Review in China for TGCT

Abbisko Cayman Limited ( (HK:2256) ) has shared an update.

Abbisko Therapeutics announced that its CSF-1R inhibitor, pimicotinib (ABSK021), has been granted Priority Review status by the China National Medical Products Administration for treating Tenosynovial Giant Cell Tumor (TGCT). This designation is expected to expedite the review process, potentially allowing quicker access for patients. Pimicotinib has previously received Breakthrough Therapy Designation from both the China NMPA and the US FDA, and Priority Medicine designation from the European Medicines Agency. The drug has shown promising results in clinical trials, meeting all primary and secondary endpoints with a significant objective response rate.

The most recent analyst rating on (HK:2256) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.

More about Abbisko Cayman Limited

Abbisko Therapeutics Co., Ltd., founded in April 2016 and based in Shanghai, is an oncology-focused biopharmaceutical company dedicated to discovering and developing innovative medicines to address unmet medical needs in China and globally. The company emphasizes precision oncology and immuno-oncology, leveraging the expertise of seasoned drug hunters with extensive research and development experience from top multinational pharmaceutical companies.

Average Trading Volume: 6,251,046

Technical Sentiment Signal: Buy

Current Market Cap: HK$5.6B

For a thorough assessment of 2256 stock, go to TipRanks’ Stock Analysis page.